New hope for advanced breast cancer: personalized drug combo trial launches
NCT ID NCT05933395
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study tests whether certain drug combinations can help people with advanced ER+/HER2- breast cancer whose disease has stopped responding to standard CDK4/6 inhibitor pills. About 135 postmenopausal women will receive one of several treatment arms based on their tumor's genetic profile. The goal is to see if these combinations can shrink tumors or keep them stable for at least 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.